M

Moderna

Develops mRNA-based medicines for health

Facilities Co-op - Plant & Project Engineering

Winter 2027, Spring 2027Updated on 10/22/2026
$20 - $60+ Annual discretionary bonus + Other incentive compensation + Equity award
Internship
Bachelor's, Master's
Norwood, MA, USA
In Person100% onsite at the Norwood site; not eligible for remote work.
Architecture & Civil EngineeringBuilding Services Engineering
No H1B Sponsorship

About the job

Requirements
  • Currently pursuing a Bachelor's or Master's degree in Chemical Engineering, Mechanical Engineering, Electrical Engineering, Industrial Engineering, Controls/Automation Engineering, Robotics/Mechatronics, Engineering Technology, Computer Science, Software Engineering, Computer Engineering, Data Science, Information Systems/Technology, or a related technical discipline.
  • Interest in engineering, manufacturing, facilities, automation and control systems, maintenance and work management, technical documentation, software/data applications, digital tools, or pharmaceutical/biotechnology operations.
  • Familiarity with basic engineering, software, data, or technical principles and an interest in applying structured problem-solving, system-level thinking, and data-driven methods to real-world technical challenges.
  • Strong written and verbal communication skills, with the ability to document work clearly and collaborate effectively with technical and cross-functional stakeholders.
  • Basic proficiency with Microsoft Excel, Word, and PowerPoint.
  • Ability to learn quickly, manage assigned tasks, incorporate feedback, and work effectively in a team-based environment.
  • Candidates must already hold U.S. work authorization and be able to maintain that status without future sponsorship.
  • Applicants must be available for the entire co-op duration, January 18, 2027 through June 25, 2027.
  • Only individuals who qualify as U.S. persons (citizens, permanent residents, asylees, or refugees) are eligible due to export-control requirements.
Responsibilities
  • Support scoped engineering, technical, or operational deliverables under the guidance of a manager or mentor.
  • Collect, organize, trend, and analyze technical or operational data to support troubleshooting, decision-making, equipment performance, maintenance and work-management activities, reliability, and continuous improvement.
  • Support structured problem-solving and troubleshooting by reviewing engineering documentation, system data, and other available information, identifying potential contributors, documenting observations, and helping evaluate practical improvements.
  • Draft and maintain GMP-compliant engineering documentation, including technical summaries, procedures, work instructions, drawings, standards, change controls, deviation/CAPA support documentation, project records, or turnover documentation, as applicable.
  • Assist with digital engineering, software/data, and knowledge-management initiatives that improve access to technical information, engineering and maintenance workflows, data quality, decision-making, and troubleshooting resources; this may include internal applications, dashboards, automated workflows, and testing and refinement of emerging AI-enabled tools where appropriate.
  • Support engineering projects and operational improvements across applicable lifecycle phases, which may include design, procurement, installation, start-up, equipment or drawing updates, system walkdowns, commissioning, qualification/validation support, project turnover, maintenance planning and scheduling, work and asset-management improvements, or other team-specific deliverables.
  • Collaborate with Engineering, Facilities, Maintenance, Manufacturing, Validation, Quality, Project Management, Digital/IT, vendors, and other stakeholders to support safe and effective execution.
  • Communicate findings, progress, and recommendations through written documentation, presentations, and cross-functional discussions.
  • Follow applicable GxP requirements, Good Documentation Practices, data-integrity expectations, company policies, SOPs, work instructions, and site safety procedures while performing assigned tasks.
  • Complete required training and actively seek learning opportunities to build technical, digital, problem-solving, and professional skills.
Desired Qualifications
  • Exposure to engineering, data analysis, CAD, CMMS, BIM, automation/controls, programming or scripting, databases, software applications, or other digital tools.
  • Prior co-op, internship, project, or lab experience.
  • GPA of 3.5 on a 4 scale or equivalent.
  • Ability to work independently and contribute to high-performing teams.

About the company

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 convertible notes raised $3 billion for oncology growth and debt flexibility.
  • April 21, 2026 European Commission approval made mCombriax the first authorized flu-COVID combo vaccine.
  • Second-quarter 2026 guidance targets up to 10% revenue growth and year-end cash of $4.7 billion.

What critics are saying

  • September 28, 2026, Delaware kept Bayer's mRNA patent case alive against Moderna.
  • July 15, 2026, Sanofi sued Moderna over COVID vaccine patents in New Jersey.
  • If intismeran fails beyond melanoma, Moderna remains a shrinking vaccine company.

What makes Moderna unique

  • Moderna's mRNA platform spans vaccines, oncology, and rare disease, unlike one-product peers.
  • September 30, 2026, Moderna added a COO to scale intismeran autogene manufacturing.
  • Bancel says Moderna owns mutation-selection software for personalized vaccines and synthetic, cell-free production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Sabbatical Leave
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 21st, 2026
Moderna soars 600% to $90B market cap, but valuation leaves no margin for error

Moderna (NASDAQ: MRNA) has soared over 600% this year, making it the best performer among large-cap healthcare stocks. Eli Lilly gained 16% and Johnson & Johnson 22%. The rally followed US approval of mFLUSIVA, an influenza vaccine for people aged 50 and older. Moderna also said its personalised cancer vaccine, intismeran autogene, significantly improved recurrence-free survival in certain melanoma patients when combined with Merck's Keytruda. It is the first personalised vaccine to produce positive Phase 3 results. Moderna's market cap now stands at $90 billion. The average analyst price target of $123.61 implies a downside of about 45%. In the first six months of 2026, revenue rose 113.6% to $534 million, but net loss widened to $2.1 billion from $1.8 billion.

Yahoo Finance
Oct 21st, 2026
ServiceNow and Kinder Morgan are large-cap picks to watch; Moderna's $96.65B value underwhelms

StockStory, a stock research service, named two large-cap stocks to watch and one to avoid. It advises steering clear of Moderna, which has a market cap of $96.65 billion. Sales fell 20.5% annually over five years, and earnings per share dropped 24.5% annually. Its free cash flow margin fell 95.9 percentage points. The stock trades at $241.71, or 44.1x forward price-to-sales. ServiceNow ($154.6 billion market cap) grew annual recurring revenue 22.3% over the last year and has a free cash flow margin of 33.4%. It trades at $148.56 per share. Kinder Morgan ($74.75 billion market cap) reported $17.96 billion in revenue. Its shares trade at $33.64, or 22.5x forward earnings.

Yahoo Finance
Oct 19th, 2026
Moderna, Chemed and 10x Genomics: three healthcare stocks to avoid despite a 25.2% sector rally

Healthcare stocks have gained 25.2% over the past six months, beating the S&P 500 by 16.3 percentage points. Even so, StockStory warns that heavy regulation can hurt earnings, and names three stocks to avoid. Moderna, valued at $87.04 billion, has seen sales fall 20.5% a year over five years. Earnings per share dropped 24.5% annually, and the stock trades at 46x forward price-to-sales. Chemed, worth $6.67 billion, grew revenue 4.1% a year over five years, slower than its peers. Its adjusted operating margin fell 3.9 percentage points, and it trades at 20x forward earnings. 10x Genomics, valued at $9.10 billion, saw revenue decline 1.2% annually over two years to $616.9 million. Its returns on capital are negative.

CNBC
Oct 14th, 2026
Merck CEO expects Moderna cancer vaccine's six-week production time to shorten

Merck chief executive officer Rob Davis expects the company's personalised cancer vaccine with Moderna to become faster to make over time. He told CNBC the current timeline is six weeks, from sequencing a patient's tumour to delivering the shot to the hospital. "I do think over time you're going to see that timeline shortened," Davis said. For now, the focus is on readying supply and the market. The vaccine targets the mutations in each patient's tumour and is paired with Merck's immunotherapy Keytruda. In August, the companies released positive initial late-stage data in melanoma patients. Trials are also under way in lung, bladder, and kidney cancers. Davis spoke as Merck opened its 120,000-square-foot research facility, Advance, in West Point, Pennsylvania.

The Hindu BusinessLine
Oct 14th, 2026
AI cannot replace clinical trials soon, warns Moderna co-founder Noubar Afeyan.

AI cannot replace clinical trials soon, warns Moderna co-founder Noubar Afeyan. Afeyan cautioned against overhyping AI's ability to cure diseases such as cancer, arguing that scientific progress must be accompanied by greater humility about what researchers understand about human physiology. Updated - October 14, 2026 at 01:03 PM. Noubar Afeyan, co-founder and chairman of Moderna In | Photo Credit: Bloomberg/ANINDITO MUKHERJEE Artificial intelligence (AI) could transform scientific discovery and accelerate drug development, but replacing clinical trials with digital simulations remains a distant prospect given the complexity of human biology, Noubar Afeyan, co-founder and chairman of Moderna, said at the Bloomberg New Economy Forum in New Delhi on Tuesday. Afeyan cautioned against exaggerated claims about AI's potential to cure diseases such as cancer, arguing that scientific progress must be accompanied by greater humility about what researchers understand about human physiology. "I think the hardest thing will be to do what is out there these days in terms of speculation, which is simulating clinical trials and avoiding them altogether," he said. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.